Research programme: anticancer therapeutics - Institute for Cancer Prevention/Integrated BioPharma
Latest Information Update: 21 Jul 2010
At a glance
- Originator Institute for Cancer Prevention; Integrated BioPharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Dec 2005 INB:Biotechnologies and City of Hope Cancer Center have entered into an agreement to conduct a phase I trial with Phytosel®
- 12 Jan 2004 Preclinical trials in Cancer in USA (unspecified route)